Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Molecular Profile | BRAF V600E |
| Therapy | Cetuximab + Encorafenib + Tazemetostat |
| Indication/Tumor Type | colorectal cancer |
| Response Type | sensitive |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|---|---|---|---|---|---|---|
| BRAF V600E | colorectal cancer | sensitive | Cetuximab + Encorafenib + Tazemetostat | Preclinical - Cell culture | Actionable | In a preclinical study, the addition of Tazverik (tazemetostat) sensitized a colorectal cancer cell line harboring BRAF V600E to treatment with the combination of Braftovi (encorafenib) and Erbitux (cetuximab) in culture, resulting in decreased cell proliferation (PMID: 39121480). | 39121480 |
| PubMed Id | Reference Title | Details |
|---|---|---|
| (39121480) | Epigenetic and oncogenic inhibitors cooperatively drive differentiation and kill KRAS-mutant colorectal cancers. | Full reference... |